<--- Back to Details
First PageDocument Content
Tyrosine kinases / Microbiology / HIV/AIDS / Virology / Nef / HCK / HIV / Integrase / Tyrosine-protein kinase CSK / Src family kinase / Proto-oncogene tyrosine-protein kinase Src / Zidovudine
Date: 2013-11-27 16:23:28
Tyrosine kinases
Microbiology
HIV/AIDS
Virology
Nef
HCK
HIV
Integrase
Tyrosine-protein kinase CSK
Src family kinase
Proto-oncogene tyrosine-protein kinase Src
Zidovudine

Title Authors Affiliations

Add to Reading List

Source URL: www.csb.pitt.edu

Download Document from Source Website

File Size: 221,06 KB

Share Document on Facebook

Similar Documents

Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso

Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso

DocID: 1uOOF - View Document

June 17, 2009   Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds    Damilola A. Adepegba, Department of Natural Sciences, University of Maryland 

June 17, 2009  Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds    Damilola A. Adepegba, Department of Natural Sciences, University of Maryland 

DocID: 1qLnJ - View Document

Title Authors Affiliations

Title Authors Affiliations

DocID: 1qIsB - View Document

GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations

GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations

DocID: 1aVDG - View Document

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

DocID: 1ai1w - View Document